API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Ocrevus (ocrelizumab) is an investigational twice-yearly, 10-minute subcutaneous injection, humanised monoclonal antibody designed to target CD20-positive B cells to treat patients with progressive and relapsing forms of MS.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Lead Product(s): Ocrelizumab,Dexamethasone,Desloratadine
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
OCREVUS (ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS).
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Ocrevus (Ocrelizumab) data will show significant benefit on slowing disease activity and progression in patients with treatment-naïve early-stage relapsing-remitting multiple sclerosis (RRMS).
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
Analysis demonstrated positive effects of OCREVUS on cognition, with 70% of patients having improved cognition, as measured with SDMT. Clinically meaningful improvement was observed in 34% of patients treated with OCREVUS and worsening in 30% of patients treated with OCREVUS.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
OCREVUS (ocrelizumab), a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
OCREVUS resulted in a 35% reduction in the risk of patients with RMS needing a walking aid over seven and a half years compared with patients who switched from interferon beta-1a to OCREVUS after the 96-week double-blind period.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Ocrevus
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
Applications are based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the currently approved OCREVUS dosing regimen.
Lead Product(s): Ocrelizumab
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020